发明名称 |
Therapeutic miRNAs for treating heart and skeletal muscle diseases |
摘要 |
The present disclosure describes the role for miR-322(424)/503 in the differentiation of cardiac precursor cells. Thus, the use of these molecules in the programming of resident stem/progenitor cells into cardiomyocytes, both in vitro and in vivo. Such methods find particular use in the treatment of patients post-myocardial infarction to prevent or limit scarring and to promote myocardial repair. |
申请公布号 |
US9439924(B2) |
申请公布日期 |
2016.09.13 |
申请号 |
US201514680785 |
申请日期 |
2015.04.07 |
申请人 |
UNIVERSITY OF HOUSTON |
发明人 |
Liu Yu;Schwartz Robert J;Shen Xiaopeng |
分类号 |
A61K48/00;A61K31/7105;A61K45/06;C12N5/077;C12N15/00 |
主分类号 |
A61K48/00 |
代理机构 |
Parker Highlander PLLC |
代理人 |
Parker Highlander PLLC |
主权项 |
1. A method of programming a residential embryonic stem cell or a residential cardiac progenitor cell into cardiac fibroblast comprising contacting said cell with miR-322/424 and/or miR-503, as well pri-miRNAs and pre-miRNAs thereof wherein said contacting results in programming of said cell into a cardiac fibroblast. |
地址 |
Houston TX US |